99mtc-annexin-v-128

Recombinant proteinexperimentalImaging agent

Clinical trial activity

2 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started Feb 5, 2016 (NCT02459613)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
No
Imaging
99-MTC

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03630835Phase 2/Phase 3 (Phase 3)Sep 30, 2018Assistance Publique - Hôpitaux de Paris
NCT02459613Phase 1/Phase 2 (Phase 2)Feb 5, 2016Advanced Accelerator Applications, Assistance Publique - Hôpitaux de Paris, Institut National de la Santé Et de la Recherche Médicale, France
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Assistance Publique - Hôpitaux de ParisAcademic/Hospital2122016
Advanced Accelerator ApplicationsFor profit1012016
Institut National de la Santé Et de la Recherche Médicale, FranceAcademic/Hospital1112016
3 organizations
Page 1 / 1